Arterial Thrombosis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Arterial Thrombosis - Pipeline Review, H1 2016', provides an overview of the Arterial Thrombosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arterial Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Arterial Thrombosis - The report reviews pipeline therapeutics for Arterial Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Arterial Thrombosis therapeutics and enlists all their major and minor projects - The report assesses Arterial Thrombosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Arterial Thrombosis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Arterial Thrombosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Arterial Thrombosis Overview 7 Therapeutics Development 8 Pipeline Products for Arterial Thrombosis - Overview 8 Pipeline Products for Arterial Thrombosis - Comparative Analysis 9 Arterial Thrombosis - Therapeutics under Development by Companies 10 Arterial Thrombosis - Therapeutics under Investigation by Universities/Institutes 11 Arterial Thrombosis - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Arterial Thrombosis - Products under Development by Companies 15 Arterial Thrombosis - Products under Investigation by Universities/Institutes 16 Arterial Thrombosis - Companies Involved in Therapeutics Development 17 Astellas Pharma Inc. 17 AstraZeneca Plc 18 Bayer AG 19 Bristol-Myers Squibb Company 20 Eisai Co., Ltd. 21 Johnson & Johnson 22 Sanofi 23 Arterial Thrombosis - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 AS-1468240 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ASP-1645 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ASP-6537 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 BAY-1213790 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 BMS-593214 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 BMS-654457 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 C-3 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 E-5539 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ER-410660 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 JNJ-375 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 PZ-128 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 SAR-216471 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 ticagrelor - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Arterial Thrombosis - Recent Pipeline Updates 51 Arterial Thrombosis - Dormant Projects 57 Arterial Thrombosis - Product Development Milestones 58 Featured News & Press Releases 58 Nov 13, 2014: AstraZeneca announces initiation of development programme for BRILINTA reversal agent 58 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables
Number of Products under Development for Arterial Thrombosis, H1 2016 8 Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Arterial Thrombosis - Pipeline by Astellas Pharma Inc., H1 2016 17 Arterial Thrombosis - Pipeline by AstraZeneca Plc, H1 2016 18 Arterial Thrombosis - Pipeline by Bayer AG, H1 2016 19 Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H1 2016 20 Arterial Thrombosis - Pipeline by Eisai Co., Ltd., H1 2016 21 Arterial Thrombosis - Pipeline by Johnson & Johnson, H1 2016 22 Arterial Thrombosis - Pipeline by Sanofi, H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Arterial Thrombosis Therapeutics - Recent Pipeline Updates, H1 2016 51 Arterial Thrombosis - Dormant Projects, H1 2016 57
List of Figures
Number of Products under Development for Arterial Thrombosis, H1 2016 8 Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Targets, H1 2016 25 Number of Products by Stage and Targets, H1 2016 25 Number of Products by Mechanism of Actions, H1 2016 27 Number of Products by Stage and Mechanism of Actions, H1 2016 27 Number of Products by Routes of Administration, H1 2016 29 Number of Products by Stage and Routes of Administration, H1 2016 29 Number of Products by Molecule Types, H1 2016 31 Number of Products by Stage and Molecule Types, H1 2016 31
Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries sRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.